scPharmaceuticals Inc. (SCPH): Price and Financial Metrics
GET POWR RATINGS... FREE!
SCPH Stock Price Chart Interactive Chart >
SCPH Price/Volume Stats
| Current price | $8.96 | 52-week high | $10.38 |
| Prev. close | $8.76 | 52-week low | $3.68 |
| Day low | $8.53 | Volume | 310,100 |
| Day high | $9.14 | Avg. volume | 542,388 |
| 50-day MA | $7.38 | Dividend yield | N/A |
| 200-day MA | $6.09 | Market Cap | 245.81M |
scPharmaceuticals Inc. (SCPH) Company Bio
scPharmaceuticals Inc. engages in the development and commercialization of transformative pharmaceutical products. The company’s under development products are for heart failure and infectious diseases that include Furoscix that is for treatment of worsening or decompensated heart failure outside of the inpatient setting. scPharmaceuticals Inc. formerly known as scPharmaceuticals LLC. and changed its name to scPharmaceuticals Inc. in March 2014. The company was founded 2013 and is based in Burlington, Massachusetts.
Latest SCPH News From Around the Web
Below are the latest news stories about SCPHARMACEUTICALS INC that investors may wish to consider to help them evaluate SCPH as an investment opportunity.
scPharmaceuticals Inc. (NASDAQ:SCPH) Q4 2022 Earnings Call TranscriptscPharmaceuticals Inc. (NASDAQ:SCPH) Q4 2022 Earnings Call Transcript March 22, 2023 PJ Kelleher: Thank you, operator. Before turning the call over to management, I would like to make the following remarks concerning forward-looking statements. All statements on this conference call, other than historical facts, are forward-looking statements within the meaning of the federal securities laws […] |
When Will scPharmaceuticals Inc. (NASDAQ:SCPH) Turn A Profit?scPharmaceuticals Inc. ( NASDAQ:SCPH ) is possibly approaching a major achievement in its business, so we would like to... |
scPharmaceuticals Inc. Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Business UpdateAnnounced launch and commercial availability of FUROSCIX® (furosemide injection), the first and only self-administered, subcutaneous loop diuretic for the at-home treatment of congestion in chronic heart failure Ended Q4 with cash, cash equivalents, restricted cash and investments of $118.4M Company to host investor conference call and webcast today, Wednesday, March 22, at 4:30pm ET BURLINGTON, Mass., March 22, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical com |
scPharmaceuticals to Announce Fourth Quarter and Full-Year 2022 Financial Results on Wednesday, March 22Management to host conference call and webcast at 4:30 p.m. ET BURLINGTON, Mass., March 15, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care, and reduce healthcare costs, today announced that scPharmaceuticals management will host a conference call and audio webcast at 4:30 p.m. ET on Wednesday, March 22, 2023, to discuss the financial res |
scPharmaceuticals to Participate in the Cowen 43rd Annual Health Care ConferenceBURLINGTON, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, President & Chief Executive Officer, is scheduled to participate in a fireside chat at the Cowen 43rd Annual Health Care Conference, on Wednesday, March 8 at 10:30 am ET in Bos |
SCPH Price Returns
| 1-mo | 14.14% |
| 3-mo | 36.17% |
| 6-mo | 48.10% |
| 1-year | 50.84% |
| 3-year | 17.12% |
| 5-year | -27.74% |
| YTD | 24.97% |
| 2022 | 42.83% |
| 2021 | -5.10% |
| 2020 | -6.54% |
| 2019 | 50.53% |
| 2018 | -68.90% |
Loading social stream, please wait...